David Wustrow

David joined RAPT Therapeutics in 2016, bringing more than 20 years of experience in drug discovery. Most recently, David served as Vice President, Chemical and Pharmaceutical Sciences at Cleave Biosciences, where he led chemistry efforts directed towards the discovery and development of first-in-class drug products for solid and hematologic malignancies. Previously, he held several escalating positions at biotechnology and pharmaceutical companies including Vice President, Medicinal Chemistry and Executive Director of Scientific Assessment and Licensing at XenoPort, Executive Director of Chemistry at Neurogen, and Senior Director of Neuroscience Chemistry at Pfizer, where he led cross-functional teams to deliver preclinical development candidates for the treatment of pain, inflammation, and psychiatric disorders.

David received his B.S. from Pennsylvania State University and holds a Ph.D. in Organic Synthesis from The University of Rochester. He is the author of over 40 peer-reviewed publications and an inventor on over 30 U.S. patents.